RNA polymerase III subunit CGenealiases: C82 · RPC3 · RPC62
Q-omics provides the consensus-scored POLR3C profile across patient tissues and cancer cell-line models. POLR3C expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, POLR3C is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, POLR3C protein abundance shows 22,047 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KIRC, and GBM as cancer lineages where POLR3C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR3C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR3C survival associations across molecular data types. POLR3C RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR3C RNA expression–survival associations across cancer types. High POLR3C expression shows unfavorable associations in KIRP, ACC, UVM, LIHC and KICH, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for POLR3C RNA expression.
This table summarizes POLR3C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for POLR3C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR3C shows higher tumor expression in KIRC, COAD, HNSC, LUAD, LIHC and KIRP. The KIRC box plot shows higher POLR3C RNA expression in tumor versus normal tissue (log2 FC = +0.714, t-test p < 0.001).
This table shows molecular features associated with POLR3C in patient tissues and cancer cell lines. In patient samples, POLR3C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR3C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
